RecruitingNCT06480201

Brain-wave patterns and ketamine response in treatment-resistant depression

About this title

Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

Read the official source — NCT06480201

Medication studyAges 21–45United States

The study in practice

Understand this study

Who could participate?

Listed age limits: 21 years to 45 years.

Listed locations: Houston, United StatesSee all locations and recruitment
Activities: Medication described in the protocol
Compensation: Payment and expense reimbursement have not been verified.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 1, 2024

Recruitment status: Recruiting
Enrollment listed in the registry: 100
Sponsor: Texas A&M University
Sponsor type: University
Study type: Drug
Intervention type: Medication / drug, OTHER
Study phase: Phase 1
Locations: United States
Age range: From 21 Years to 45 Years
Official registry ID: NCT06480201
Official title: Show the full official title
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

Questions about this study?

The HopeStage team will email you.

Recruitment & locations

Recruiting

Houston

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Texas A&M University, a university.

Does this study involve medication?

Yes. The study involves medication, including ketamine.

Who can participate?

Listed age limits: 21 years to 45 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me